JONA Biotechnology

LONSURF is specifically a combination drug of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, used to treat adult patients with: metastatic colorectal cancer who have been previously treated with medicine fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with minimum two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if apt, HER2/neu-targeted therapy.


Dosage: The recommended dosage of lonsurf is 35 mg/m2 up to a maximum of 80 mg per dose (based on the trifluridine component) orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle until the disease is progressive or unacceptable toxicity occurs. Round dose to the nearest 5 mg increment. Instruct patients to swallow lonsurf tablets whole. Instruct patients not to retake doses of lonsurf that are vomited or missed and to continue with the next scheduled dose.